hb0052
Small moleculeexperimental
Clinical trial activity
1 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2024 (NCT06992687)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- 5'-nucleotidaseINHIBITOR
NT5E inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06992687 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2024 | Central South University, Chinese Academy of Medical Sciences, Harbin Medical University, Huazhong University of Science and Technology, Nanjing University, Peking University, Shandong University, Zhejiang Huahai Pharmaceutical Co., Ltd. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Harbin Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Nanjing University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Shandong University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | For profit | 1 | 1 | 1 | 2024 |
8 organizations
Page 1 / 1